Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222493 · ClinicalTrials.gov registry record · Phase 3
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 650
- Enrollment target
NCT02222493 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 650 participants.
The verdict
NCT02222493, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 650 participants
- Enrollment target
Study Summary
The study will assess the efficacy and safety of PF-06438179 and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate.
Interventions
- BIOLOGICAL Infliximab
- BIOLOGICAL PF-06438179
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2014-08-26 |
| Est. Completion | 2017-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222493
The ClinicalTrials.gov registry entry for NCT02222493 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Infliximab is the first listed.
NCT02222493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02222493 about?
NCT02222493 is a clinical study titled "A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).". The study will assess the efficacy and safety of PF-06438179 and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate.
What is the current status of trial NCT02222493?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2014-08-26. Estimated completion is 2017-06-01.
What interventions are being tested in trial NCT02222493?
The interventions under investigation include: Infliximab (BIOLOGICAL), PF-06438179 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02222493?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.